frontline therapy cohort has just started I believe.
this means we have identified the optimal dose, toxicity levels are within appetite (likely very low given NK therapy is generally well tolerated), we have received all the approvals to proceed. Presumably, data collation has commenced for the first prelim data read out.
Importantly, the dose escalation is with AML patients who have R/R AML and failed other treatments (as opposed to front line).
Dr Maiti from MD Anderson expects that efficacy from CORE NK will improve when given as front line therapy because the patient’s immune system would generally be in better shape and the AML disease burden in the bone marrow would be lower (because the disease is less advanced).
furthermore we are combining CORE NK as a triplet therapy so I hope this will produce some stellar results, perhaps surpassing the already promising results in the Case Western Core NK trial. (Albeit with diff patient profiles)
CHM Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)